United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat (NASDAQ:UTHR)

6 mins read

At a Glance

United Therapeutics’ (NASDAQ:UTHR) Q2 performance underscores robust financials with a notable 27.7% YoY revenue increase, fueling investor optimism. On the clinical front, the transition to Tyvaso DPI (Dry Powder Inhaler) reveals a calculated strategic pivot aimed

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Defense Secretary Austin says US is ‘concerned about potential escalation’ in Middle East

Next Story

Chinese drug firms backed by global banks found using leopards and pangolins parts, group says

Latest from News